Published in J Virol on November 01, 2000
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol (2002) 2.53
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A (2010) 2.44
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog (2010) 2.28
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol (2006) 1.99
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol (2004) 1.98
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol (2008) 1.63
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog (2009) 1.56
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol (2011) 1.49
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog (2012) 1.41
Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol (2006) 1.38
CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol (2003) 1.38
Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (2004) 1.37
Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol (2006) 1.35
Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology (2012) 1.31
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol (2013) 1.20
Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol (2001) 1.19
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding. J Virol (2007) 1.15
Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem (2009) 1.14
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Crystal structure of glycoprotein E2 from bovine viral diarrhea virus. Proc Natl Acad Sci U S A (2013) 1.10
Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One (2009) 1.10
Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J Virol (2003) 1.09
Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol (2002) 1.06
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
Neutralizing antibody response to hepatitis C virus. Viruses (2011) 1.03
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol (2008) 1.03
A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol (2008) 1.02
Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol (2014) 0.99
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest (2014) 0.99
Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J Virol (2006) 0.98
Antibody-dependent enhancement of hepatitis C virus infection. J Virol (2007) 0.96
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol (2014) 0.96
Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog (2014) 0.96
Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol (2013) 0.95
Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. J Virol (2014) 0.95
Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology (2011) 0.92
Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. J Virol (2006) 0.89
Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein. Biochim Biophys Acta (2008) 0.89
Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. J Virol (2013) 0.89
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem (2011) 0.88
Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. J Virol (2016) 0.85
Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem (2015) 0.85
Spatiotemporal analysis of hepatitis C virus infection. PLoS Pathog (2015) 0.85
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J Gen Virol (2011) 0.85
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J (2007) 0.81
Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain. J Biol Chem (2009) 0.80
A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. J Virol (2016) 0.80
An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection. J Virol (2015) 0.78
Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection. J Virol (2016) 0.78
Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol (2014) 0.78
Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. Hepatology (2016) 0.78
Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol (2016) 0.77
Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virions. Int J Hepatol (2010) 0.77
Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. Proc Natl Acad Sci U S A (2016) 0.77
Expression and immunoreactivity of HCV/HBV epitopes. World J Gastroenterol (2005) 0.76
Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. J Virol (2016) 0.76
Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells. J Immunol (2016) 0.76
The hepatitis C virus E1 glycoprotein undergoes productive folding but accelerated degradation when expressed as an individual subunit in CHO cells. PLoS One (2011) 0.75
An optimized hepatitis C virus E2 glycoprotein core adopts a functional homodimer that efficiently blocks virus entry. J Virol (2016) 0.75
Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. MBio (2017) 0.75
Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World J Hepatol (2015) 0.75
Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A (1991) 14.05
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis (1995) 5.53
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A (1992) 4.47
Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology (1991) 4.47
Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol (1994) 4.21
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol (1998) 4.01
Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A (1994) 3.76
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun (1991) 3.09
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol (1994) 3.06
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol (1993) 2.74
Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol (1993) 2.58
Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc Natl Acad Sci U S A (1995) 2.45
Genotypic analysis of hepatitis C virus in American patients. Hepatology (1994) 2.33
Limited humoral immunity in hepatitis C virus infection. Gastroenterology (1999) 2.31
Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells. Virology (1993) 1.92
Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med (1997) 1.92
Hemadsorption and fusion inhibition activities of hemagglutinin analyzed by vaccinia virus mutants. Virology (1990) 1.58
High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology (1998) 1.50
Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology (1998) 1.48
Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol (2000) 1.48
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology (1998) 1.37
Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol (1995) 1.33
Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med (1998) 1.29
Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology (1998) 1.21
Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J Virol (1997) 1.06
Isolation and characterization of human monoclonal antibodies against hepatitis C virus envelope glycoproteins. J Med Virol (1998) 0.97
Establishment of a cell line constitutively expressing E2 glycoprotein of hepatitis C virus and humoral response of hepatitis C patients to the expressed protein. J Gen Virol (1995) 0.94
Stabilizing antibody secretion of human Epstein Barr virus-activated B-lymphocytes with hybridoma formation by electrofusion. Methods Mol Biol (1995) 0.92
Is CD81 the key to hepatitis C virus entry? Hepatology (1999) 0.92
Attachment of hepatitis C virus to cultured cells: a novel predictive factor for successful interferon therapy. J Med Virol (1998) 0.82
Management of posttransplantation viral hepatitis--hepatitis B. Liver Transpl Surg (1998) 0.81
The sequence of the human genome. Science (2001) 101.55
Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine. Lancet (1995) 24.14
A gene map of the human genome. Science (1996) 14.32
Binding of hepatitis C virus to CD81. Science (1998) 12.40
A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med (2001) 7.99
Construction and characterization of an SV40 mutant defective in nuclear transport of T antigen. Cell (1984) 5.81
Accounting for unmeasured population substructure in case-control studies of genetic association using a novel latent-class model. Am J Hum Genet (2001) 5.66
Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science (1996) 5.55
A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev (1998) 5.14
Controlled trial of direct physician order entry: effects on physicians' time utilization in ambulatory primary care internal medicine practices. J Am Med Inform Assoc (2001) 5.13
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Induction of nuclear transport with a synthetic peptide homologous to the SV40 T antigen transport signal. Cell (1986) 4.56
The tetraspanin superfamily: molecular facilitators. FASEB J (1997) 4.29
DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol (2001) 4.22
5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol (2000) 3.94
Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol Microbiol (1998) 3.79
Views of elderly patients and their relatives on cardiopulmonary resuscitation. BMJ (1994) 3.64
An STS-based radiation hybrid map of the human genome. Genome Res (1997) 3.57
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol (2001) 3.55
Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci (2000) 3.45
Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. Palliat Med (1997) 3.31
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis (1997) 3.29
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol (2000) 3.17
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet (1996) 2.96
Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med (1992) 2.92
Mortality associated with congenital heart defects in the United States: trends and racial disparities, 1979-1997. Circulation (2001) 2.92
The effects of variations in the number and sequence of targeting signals on nuclear uptake. J Cell Biol (1988) 2.89
Electrostatic interactions among hydrophobic ions in lipid bilayer membranes. Biophys J (1978) 2.80
Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet (2001) 2.78
Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology (1998) 2.72
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology (1999) 2.66
Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol (2001) 2.66
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology (2000) 2.65
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol (1990) 2.60
Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med (1994) 2.56
Leader sequences of Strongylocentrotus purpuratus histone mRNAs start at a unique heptanucleotide common to all five histone genes. Proc Natl Acad Sci U S A (1980) 2.54
An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet (2005) 2.39
Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol (2000) 2.32
Activations related to "mirror" and "canonical" neurones in the human brain: an fMRI study. Neuroimage (2003) 2.31
Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol (1999) 2.26
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood (2001) 2.26
Follow-up families who experience a perinatal death. Pediatrics (1978) 2.22
A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol (1998) 2.20
Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science (2014) 2.20
The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol (1992) 2.17
T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature (1988) 2.15
Transmission disequilibrium test (TDT) when only one parent is available: the 1-TDT. Am J Epidemiol (1999) 2.15
Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A (2003) 2.15
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun (1996) 2.14
Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J (2001) 2.12
Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke (1999) 1.98
Identification of four nuclear transport signal-binding proteins that interact with diverse transport signals. Mol Cell Biol (1989) 1.97
Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology (2001) 1.94
Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med (1997) 1.92
Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell (1986) 1.92
CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J (2001) 1.90
Ultrasonography for diagnosis of acute appendicitis: results of a prospective multicenter trial. Acute Abdominal Pain Study Group. World J Surg (1999) 1.90
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med (1993) 1.90
Doctors' knowledge of the cost of common medications. J Clin Hosp Pharm (1986) 1.87
Biosynthesis and stability of globin mRNA in cultured erythroleukemic Friend cells. Cell (1976) 1.85
Diagnostic scores for acute appendicitis. Abdominal Pain Study Group. Eur J Surg (1995) 1.85
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol (1997) 1.82
V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood (2001) 1.79
Sequence of the 5'-end of Strongylocentrotus purpuratus H2b histone mRNA and its location within histone DNA. Nature (1979) 1.77
Prevalence of human respiratory viruses in adults with acute respiratory tract infections in Beijing, 2005-2007. Clin Microbiol Infect (2009) 1.76
Pandemic (H1N1) 2009 virus outbreak in a school in London, April-May 2009: an observational study. Epidemiol Infect (2009) 1.76
New approaches to understanding p53 gene tumor mutation spectra. Mutat Res (1999) 1.75
The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood (2001) 1.75
Cloned hepatitis delta virus cDNA is infectious in the chimpanzee. J Virol (1989) 1.75
Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis (1986) 1.72
Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol (2000) 1.70
Cytologic grading of invasive breast carcinoma. Correlation with clinicopathologic variables and predictive value of nodal metastasis. Acta Cytol (2000) 1.68
Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol (2001) 1.67
Promoter prediction in the human genome. Bioinformatics (2001) 1.67
TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol (1990) 1.65
Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. J Virol (1993) 1.65
Relationships between B-lineage lymphocytes and stromal cells in long-term bone marrow cultures. Eur J Immunol (1987) 1.64
Carboxy-terminal truncations of the HBV core protein affect capsid formation and the apparent size of encapsidated HBV RNA. Virology (1993) 1.62
Diagnosis of latent tuberculosis infection in bacille Calmette-Guérin vaccinated subjects in China by interferon-gamma ELISpot assay. Int J Tuberc Lung Dis (2010) 1.61
Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol (1992) 1.61
Antigenic relationship of SV40 early proteins to purified large T polypeptide. Virology (1979) 1.61
Assembly, annotation, and integration of UNIGENE clusters into the human genome draft. Genome Res (2001) 1.60
Consultative geriatric assessment for ambulatory patients. A randomized trial in a health maintenance organization. JAMA (1990) 1.60
Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med (1997) 1.59
Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene (2001) 1.57
Individual genomes instead of race for personalized medicine. Clin Pharmacol Ther (2008) 1.56
Coronary artery bypass graft surgery patients and their family member caregivers: outcomes of a family-focused staged psychoeducational intervention. Appl Nurs Res (2000) 1.55
Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol (2000) 1.55
Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density. Proc Natl Acad Sci U S A (1994) 1.55
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A (1999) 1.55
Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol (1998) 1.54
The value of apparent diffusion coefficient maps in early cerebral ischemia. AJNR Am J Neuroradiol (2001) 1.54